PharmExec Picks:
Having trouble viewing this e-mail? Click here.
feed back

Update My Profile | Advertise With Us | Visit PharmExec.com |
PRINT SUBSCRIBE | DIGITAL SUBSCRIBE


Pharm Exec Picks is a biweekly eletter that delivers the most popular news and articles from the pharma space and highlights what's trending on social media.

Top 5 Stories :
What’s Ahead for 2015? Pharm Exec's Industry Outlook
Following a year where a phenomenal cure was met by pricing outrage, the march of new products, including vaccines for malaria and dengue fever, and promising immunotherapy cancer combos will continue in 2015.
Read more
Pharm Exec's Pharma 50 2014
Therapeutic specialization, competitive differentiation, and a finely-tailored value proposition are creating a new drug world of bespoke market niches—and infinite future possibilities for the best of this year's Pharma 50.
Read more
Marketing: Ready for the Next War?
Pharmaceutical marketing organizations are usually better equipped to fight the last war rather than the next one. But success, in war and in marketing, usually goes to the side which accepts and acts on the challenges of the new environment more rapidly.
Read more
2015 Pipeline Report: Burning Bright
Tracking new therapies as they wind their way through development, regulatory approval, and payer acceptance can be like waiting for paint to dry and then repainting in a different color. It's a slow process and far from linear.
Read more
Shire CEO – Almost Ideal Timing for NPS Deal
Shire’s play to acquire New Jersey-based NPS Pharma comes at nearly ideal timing for the Dublin, Ireland-headquartered firm.
Read more
Trending on Social Media :
Beyond the Blame Game: How Pharma is Learning to Collaborate
Under the Affordable Care Act, the US made great strides in extending health coverage to millions of people who previously had none. Nevertheless, for many people who struggle with chronic illnesses, paying for medical care is a challenge.
Read more
The Industry's Score on Five Key Performance Measures
At the start of a new year that also ranks "high on the five," it's appropriate to assess industry's progress. Here, in no assigned order, is our update on the five criteria and whether the industry deserves a check or a minus in moving forward on each.
Read more
VC Optimism to China: Leading Biologics Company Raises $100m C Round
2014 was a banner year for investment in biotech, and there is little sign of decline. With an unprecedented $100m Series C round of financing, Innovent has demonstrated this optimism extends as far as China.
Read more
Follow Us